Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications

123Citations
Citations of this article
101Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Human cathelicidin LL-37, a host defense peptide derived from leukocytes and epithelial cells, plays a crucial role in innate and adaptive immunity. Not only does LL-37 eliminate pathogenic microbes directly but also modulates host immune responses. Emerging evidence from tumor biology studies indicates that LL-37 plays a prominent and complex role in carcinogenesis. Although overexpression of LL-37 has been implicated in the development or progression of many human malignancies, including breast, ovarian and lung cancers, LL-37 suppresses tumorigenesis in gastric cancer. These data are beginning to unveil the intricate and contradictory functions of LL-37. The reasons for the tissue-specific function of LL-37 in carcinogenesis remain to be elucidated. Here, we review the relationship between LL-37, its fragments and cancer progression as well as discuss the potential therapeutic implications of targeting this peptide. © 2010 UICC.

Cite

CITATION STYLE

APA

Wu, W. K. K., Wang, G., Coffelt, S. B., Betancourt, A. M., Lee, C. W., Fan, D., … Cho, C. H. (2010, October 15). Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. International Journal of Cancer. https://doi.org/10.1002/ijc.25489

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free